Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
4,349.70
+20.70 (0.48%)
May 26 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,324.50 - 4,422.00
52 week 3,423.00 - 5,870.00
Open 4,344.00
Vol / Avg. 2.07M/1.81M
Mkt cap 25.54B*
P/E 28.30
Div/yield 15.32*
EPS 1.54*
Shares 593.26M
Beta     -
Inst. own     -
*GBP
Jul 27, 2016
Q2 2016 Shire PLC Earnings Release Add to calendar
May 27, 2016
Shire PLC Ordinary Shareholders Meeting - 8:00AM GMT+1 - Add to calendar
May 4, 2016
Shire PLC at Deutsche Bank Health Care Conference
Apr 29, 2016
Q1 2016 Shire PLC Earnings Call
Apr 29, 2016
Q1 2016 Shire PLC Earnings Release
Apr 28, 2016
Shire PLC Annual Shareholders Meeting
Apr 27, 2016
Shire PLC Annual Shareholders Meeting (Estimated)
Mar 8, 2016
Shire PLC at Cowen Health Care Conference - Webcast
Mar 1, 2016
Shire PLC at Credit Suisse One-on-One Healthcare Conference
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 23.96% 20.88%
Operating margin 31.82% 22.12%
EBITD margin - 44.15%
Return on average assets 8.08% 8.86%
Return on average equity 16.32% 14.47%
Employees 5,548 -
CDP Score - 91 B

Address

5 Riverwalk Citywest Business Campus, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company focuses its development resources on projects in various therapeutic areas (TAs), including rare diseases, neuroscience, ophthalmics, hematology and gastrointestinal (GI), and focuses its early development projects primarily on rare diseases. Its products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ, ADDERALL XR, INTUNIV, LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Ginger Gregory Chief Human Resource Officer
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 52
Phil J. Vickers Head of Research and Development
Age: 55
Oliver Strawbridge Senior Assistant Company Secretary
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 57
Olivier Bohuon Non-Executive Director
Age: 56
Gail D. Fosler Non-Executive Director
Age: 68
Sara Mathew Non-Executive Director
Age: 60